A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE3

מצבים רפואיים

Alzheimer Disease · Psychosis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Gilbert Neurology Partners/CCT Research, Gilbert, Arizona, United States

    Contact: Study coordinator (Jonathan Hodgson) · 602-761-9631
  • Inland Psychiatric Medical Group., Chino, California, United States

    Contact: Study coordinator (Nandita Puchakayala) · 909-488-9116
  • Local Institution - 0001, Naples, Florida, United States

  • Local Institution - 1401, Naples, Florida, United States

  • Local Institution - 0029, Cleveland, Ohio, United States

  • Insight Clinical Trials LLC - Independence, Independence, Ohio, United States

    Contact: Study coordinator (Mark Stillman) · 216-444-8897
  • Local Institution - 0020, Macquarie Park, New South Wales, Australia

  • Local Institution - 0052, Nedlands, Western Australia, Australia

  • Local Institution - 0054, Toronto, Ontario, Canada

  • Local Institution - 0027, Whitby, Ontario, Canada

  • Local Institution - 0025, Montreal, Quebec, Canada

  • Local Institution - 0040, Suita, Osaka, Japan

  • Local Institution - 0035, Nankoku-shi, Japan

  • Local Institution - 0034, Osaka, Japan

  • Local Institution - 0005, Exeter, Devon, United Kingdom

  • Local Institution - 0023, London, England, United Kingdom

  • Local Institution - 0015, Oxford, Oxfordshire, United Kingdom

  • Local Institution - 0009, Chertsey, Surrey, United Kingdom

  • Local Institution - 0017, Sheffield, Yorkshire and the Humber, United Kingdom

  • Local Institution - 0018, Crowborough, United Kingdom

  • Local Institution - 0024, London, United Kingdom

  • Local Institution - 0004, Motherwell, United Kingdom

מובילי המחקר
  • Bristol-Myers Squibb

    Study Director

    Bristol-Myers Squibb